AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05972083
Drug: Analgesia management; group S and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Trial: NCT05203315
Drug: Duobrii 0.01 % / 0.045 % Topical Lotion
RxNorm normalized name: Duobrii 0.01 % / 0.045 % Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
Trial: NCT05203315
Drug: CeraVe, Topical Cream
RxNorm normalized name: CeraVe, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
Trial: NCT04901975
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
Trial: NCT03994471
Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
Trial: NCT05255822
Drug: INNA-051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid for intra-nasal administration
Trial: NCT04910646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without orange peel fermentation
Trial: NCT06098027
Drug: [14C]CS0159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of 4mg \[14C\]CS0159
Trial: NCT04879368
Drug: Trifluridine/Tipracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Trial: NCT01464762
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
Trial: NCT05712811
Drug: CRYOTHERAPY
RxNorm normalized name: cryotherapy wart removal device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
Trial: NCT05031351
Drug: Withania somnifera
RxNorm normalized name: WITHANIA SOMNIFERA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuclear Factor Kappa Beta Inhibitor
Trial: NCT05031351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT05078385
Drug: AGLE-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
Trial: NCT05053308
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
Trial: NCT05053308
Drug: Sublingual Tablet
RxNorm normalized name: Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
Trial: NCT04766931
Drug: FB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Trial: NCT05895773
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
Trial: NCT04766931
Drug: FB2001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Trial: NCT05077631
Drug: ACD856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
Trial: NCT05077631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT05077631
Drug: ACD856 (fed cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
Trial: NCT05872347
Drug: SPH4336 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
Trial: NCT05192642
Drug: Data on other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real word data
Trial: NCT06231966
Drug: Combination therapy of high-intensity dose rosuvastatin and ezetimibe
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
Trial: NCT06231966
Drug: Rosuvastatin monotherapy for treat-to-target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
Trial: NCT06371482
Drug: Chemotherapy drug of EP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks.
Trial: NCT06082583
Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
Trial: NCT06147271
Drug: SGLT2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
Trial: NCT04270877
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Trial: NCT06055374
Drug: BxC-I17e
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form : solution for injection
Trial: NCT06055374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form : solution for injection
Trial: NCT05387642
Drug: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose with a washout period between doses
Trial: NCT05387642
Drug: 10 mg PRAX-114 or 20 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment for 28 days
Trial: NCT04947501
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Trial: NCT04753515
Drug: dexmedetomidine combined with midazolam and remifentanil.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
Trial: NCT04753515
Drug: propofol combined with midazolam and remifentanil.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
Trial: NCT04947501
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.
Trial: NCT06302062
Drug: Tumor Associated Lymph node T cell
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
Trial: NCT06302062
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
Trial: NCT05750745
Drug: Sensodyne Sensitivity & Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
Trial: NCT05691712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC as add-on to the pre-trial background medication.
Trial: NCT06696833
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 1000mg/m2 on days -5 to -3, the infusion dose is adjusted according to the subject's condition
Trial: NCT05628116
Drug: XC243 50 mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
Trial: NCT05628116
Drug: XC243 100 mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
Trial: NCT05628116
Drug: Placebo single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (1 or 2 tablets once)
Trial: NCT05628116
Drug: XC243 200 mg single-dose food effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
Trial: NCT05628116
Drug: Placebo single-dose food effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
Trial: NCT05628116
Drug: XC243 200 mg multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
Trial: NCT05628116
Drug: Placebo multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
Trial: NCT04120402
Drug: EP-104IAR 25 mg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL intra-articular injection
Trial: NCT04120402
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL intra-articular injection
Trial: NCT05711628
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05683249
Drug: NRCT-101-SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
Trial: NCT05683249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06017141
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via injection
Trial: NCT04816682
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
Trial: NCT06504875
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 bid po, d1-d14
Trial: NCT04879134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline placebo injection~Other Names:~• Saline
Trial: NCT05634213
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
Trial: NCT05392764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching empagliflozin 10 mg
Trial: NCT06045806
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06102174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06510283
Drug: Taitacept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
Trial: NCT06530966
Drug: ICP-332 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive ICP-332 tablets orally as per the protocol
Trial: NCT06025084
Drug: Egg Shell nanoparticles
RxNorm normalized name: egg shell membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
Trial: NCT06530966
Drug: ICP-332 Placebo Tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Trial: NCT05973253
Drug: prepared drop of medroxy progestrone acetat 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
Trial: NCT06584058
Drug: HPP737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]HPP737 oral preparation, 20mg（150μCi）, once
Trial: NCT04887285
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
Trial: NCT06306274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment
Trial: NCT06039163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
Trial: NCT05683301
Drug: Perindopril + Indapamide
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single pill combination of dual antihypertensive agent
Trial: NCT05683301
Drug: Amlodipine + Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill combination of dual antihypertensive agent
Trial: NCT05877547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection of matching placebo
Trial: NCT03934905
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Trial: NCT04676802
Drug: NSAID capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
Trial: NCT04676802
Drug: Opioid capsule
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
Trial: NCT04939428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
Trial: NCT05407220
Drug: HCP1904-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take it once per period
Trial: NCT05407220
Drug: HCP1904-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take it once per period
Trial: NCT06233630
Drug: Control Test - spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peripheral nerve block Only spinal anesthesia
Trial: NCT06095206
Drug: GenSci094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
Trial: NCT06536036
Drug: SIM0270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use according to the prescribed protocol
Trial: NCT04940546
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mode of administration: Orally
Trial: NCT06205082
Drug: LIT-00814
RxNorm normalized name: ZINC OXIDE 20.8 g in 100 mL TOPICAL SPRAY [Glow Baby Super Lit SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIT-00814 is an oral tablet.